Table 1.

Characteristics of COVID-19 patients with and without cancer

COVID-19 patients with cancer (n = 105)COVID-19 patients without cancer (n = 536)P
Age (years; median/IQR)64.00/14.0063.50/14.000.25
Sex
 Male57/54.72%245/45.71%0.11
 Female48/45.28%291/54.29%0.11
In-hospital infection20/19.04%8/1.49%<0.01
Smoking36/34.28%46/8.58%<0.01
Comorbidities
 Hypertension30/28.57%130/24.25%0.40
 Cardiovascular disease12/11.43%39/7.28%0.17
 Diabetes7/6.67%29/5.41%0.64
 Cerebrovascular disease5/4.76%21/3.92%0.60
 Chronic kidney disease6/5.71%22/4.10%0.44
 Chronic liver disease7/6.67%35/6.53%1.00
Signs and symptoms
 Fever68/64.76%401/74.81%0.04
 Dry cough57/52.29%313/58.40%0.45
 Sputum production16/15.24%58/10.82%0.24
 Fatigue30/28.57%179/33.40%0.36
 Myalgia6/5.71%38/7.09%0.83
 Nausea or vomiting6/5.71%41/7.65%0.68
 Chest distress15/14.29%36/6.16%0.02
 Headache7/6.67%28/5.22%0.49
 Sore throat11/10.48%43/8.02%0.44
Treatments
 Antibiotic treatments81/77.14%361/67.35%0.05
 Antiviral treatments75/71.43%372/69.40%0.68
 Systemic glucocorticoids19/18.10%78/14.55%0.35
 Oxygen therapy48/45.71%221/42.02%0.48
 Noninvasive mechanical ventilation11/10.48%47/8.77%0.58
 Invasive mechanical ventilation11/10.48%15/2.79%<0.01
 Continuous renal replacement therapy4/3.81%3/0.56%<0.01
 Extracorporeal membrane oxygenation3/2.86%2/0.37%<0.01
Time since cancer diagnosis to hospitalization
 <3 months29/27.61%NANA
 3–6 months17/16.19%NANA
 6 months–1 year11/10.47%NANA
 1–3 years19/18.09%NANA
 >3 years19/18.09%NANA
 Missing10/9.52%NANA
Metastatic cancer17/16.19%NANA
Cancer treatments within 40 days
 Surgery8/7.62%NANA
 Radiotherapy13/12.38%NANA
 Chemotherapy17/16.19%NANA
 Targeted therapy4/3.81%NANA
 Immunotherapy6/5.71%NANA
  • Note: Data are presented as median (IRQ) or n (%). P values denoted the comparison between COVID-19 patients with cancer and without cancer.

  • Abbreviation: NA, not applicable.